Transdermal delivery of allopurinol-loaded nanostructured lipid carrier in the treatment of gout
Abstract Background Allopurinol (ALP), a xanthine oxidase inhibitor, is a first line drug for the treatment of gout and hyperuricemia. Being the member of BCS class II drugs, ALP has solubility problem, which affects its bioavailability. Also, ALP has shorter half-life and showed GI related problems...
Saved in:
Main Authors: | Zakir Ali (Author), Fakhar ud Din (Author), Fatima Zahid (Author), Saba Sohail (Author), Basalat Imran (Author), Salman Khan (Author), Maimoona Malik (Author), Alam Zeb (Author), Gul Majid Khan (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2022-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Nanostructured Lipid Carriers: A Groundbreaking Approach for Transdermal Drug Delivery
by: Iti Chauhan, et al.
Published: (2020) -
Effect of nanostructured lipid carriers on transdermal delivery of tenoxicam in irradiated rats
by: Saud Bawazeer, et al.
Published: (2020) -
Augmented Oral Bioavailability and Prokinetic Activity of Levosulpiride Delivered in Nanostructured Lipid Carriers
by: Sadia Tabassam Arif, et al.
Published: (2022) -
Advance in transdermal delivery of calcitonin using nanostructured lipid carrier-based emulgel
by: Zahrotunisa, et al.
Published: (2023) -
Metformin HCl-loaded transethosomal gel; development, characterization, and antidiabetic potential evaluation in the diabetes-induced rat model
by: Kainat Nousheen, et al.
Published: (2023)